文献速递肿瘤 PET/CT

乳腺癌患者良性淋巴组织假阳性68Ga-FAPI摄取一例

False-Positive 68Ga-Fibroblast Activation Protein-Specific Inhibitor Uptake of Benign Lymphoid Tissue in a Patient With Breast Cancer.
PubMed 文献 · Clin Nucl Med · 2021-01-01

一例左乳外下象限乳腺癌患者先后接受18F-FDG PET/CT与68Ga-FAPI-04 PET/CT,FAPI在原发瘤及腋窝淋巴结的摄取高于FDG,但同侧乳腺内下象限另一结节样病灶的局灶性FAPI摄取经Tru-Cut活检证实为良性淋巴组织,提示乳腺内FAPI摄取不应一律判为恶性,需病理确认。

要点

  • 68Ga-FAPI-04在原发瘤和腋窝淋巴结的摄取高于18F-FDG。
  • 乳腺内局灶性FAPI摄取可见于良性淋巴组织,属假阳性。
  • 乳腺FAPI摄取不能一律判为恶性,需组织病理学确认。

核心结论

  • 乳腺组织中的FAPI摄取并非均提示恶性,本病例中同侧乳腺另一结节样病灶的局灶性摄取经活检证实为良性淋巴组织。

研究设计与样本

  • 单例病例报告:一例左乳外下象限乳腺癌患者先后行18F-FDG PET/CT与68Ga-FAPI-04 PET/CT,并对同侧乳腺内下象限另一结节样病灶行Tru-Cut活检。

主要发现

  • 68Ga-FAPI-04 PET/CT在原发肿瘤和腋窝淋巴结的放射性示踪剂聚集高于18F-FDG PET/CT。
  • 同侧乳腺内下象限另一结节样病灶可见局灶性FAPI摄取增高,曾被考虑为恶性。
  • 该病灶Tru-Cut活检报告为良性淋巴组织。

临床怎么用

  • 判读乳腺内FAPI局灶性摄取时需警惕良性淋巴组织等假阳性可能,不应仅凭摄取增高判定恶性。
  • 对可疑的乳腺FAPI摄取病灶应行组织病理学确认。

局限性

  • 本文为单例病例报告,结论的外推需更多病例验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-fibroblast activation protein-specific inhibitor (FAPI)-04 PET/CT was performed in a patient with left lower outer quadrant breast cancer who had 18F-FDG PET/CT imaging. 68Ga-FAPI-04 PET/CT showed higher accumulation of radiotracer in primary tumor and axillary lymph nodes than 18F-FDG PET/CT. In addition, focal increased FAPI uptake was observed in another nodular lesion in the lower inner quadrant in the same breast, which was considered malignant. However, Tru-Cut biopsy of this lesion was reported as benign lymphoid tissue. This case showed that all FAPI accumulation in breast tissue should not be interpreted in favor of malignancy; histopathological confirmation is required.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gündoğan C, Güzel Y, Can C, et al. False-Positive 68Ga-Fibroblast Activation Protein-Specific Inhibitor Uptake of Benign Lymphoid Tissue in a Patient With Breast Cancer. Clin Nucl Med. 2021. PMID: 33782295. doi:10.1097/RLU.0000000000003594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。